

TD 95/33 - Income tax: when are 'Factor (f)' payments derived by pharmaceutical companies?

 This cover sheet is provided for information only. It does not form part of *TD 95/33 - Income tax: when are 'Factor (f)' payments derived by pharmaceutical companies?*

 This document has changed over time. This is a consolidated version of the ruling which was published on *29 June 1995*

This Determination, to the extent that it is capable of being a 'public ruling' in terms of Part IVAAA of the *Taxation Administration Act 1953*, is a public ruling for the purposes of that Part. Taxation Ruling TR 92/1 explains when a Determination is a public ruling and how it is binding on the Commissioner. Unless otherwise stated, this Determination applies to years commencing both before and after its date of issue. However, this Determination does not apply to taxpayers to the extent that it conflicts with the terms of a settlement of a dispute agreed to before the date of issue of the Determination (see paragraphs 21 and 22 of Taxation Ruling TR 92/20).

Taxation Determination

Income tax: when are 'Factor (f)' payments derived by pharmaceutical companies?

1. Payments derived by pharmaceutical companies under the Factor (f) program are assessable under either subsection 25(1) or paragraph 26(g) of the *Income Tax Assessment Act 1936*. For the reasons set out in Taxation Ruling IT 2669, recipients of Factor (f) payments should account for them by the method that is most appropriate to their business operations. However, subject to section 19, they would generally be regarded as being derived when received by the taxpayer. It is at this time that the recipient has to account for the payments for tax purposes.
2. Prices for pharmaceutical products listed under the Pharmaceutical Benefits Scheme are negotiated by the Pharmaceutical Benefits Pricing Authority and pharmaceutical companies. One of the eight factors to be considered when negotiating prices is the level of Australian activity pricing guideline known as Factor (f) which allows for higher notional prices to be paid to a company in return for approved programs of development and a significant commitment to local production, research and development.

Commissioner of Taxation

29/06/95

FOI INDEX DETAIL: Reference No. I 1015836
Related Determinations: TD 93/18
Related Rulings: IT 2669
Subject Ref: bounty; subsidy
Legislative Ref: ITAA 19; ITAA 25(1); ITAA 26(g)
Case Ref:
ATO Ref: AULC 11/711 (Way); NAT 95/4526-3

Previously issued as Draft TD 93/D228

ISSN 1038 - 8982